Enovix stock rallies on sales forecast
Shares of Enovix Corp. (ENVX) rallied after hours on Tuesday after the lithium-ion battery maker forecast fourth-quarter sales that were far above expectations, helped by an acquisition and demand from the U.S. Army. The company -- whose products are used by makers of smartphones and other electronic devices, along with medical equipment and power tools -- said it expected fourth-quarter sales of between $3 million and $4 million, compared with FactSet forecasts for $500,000. Management said that forecast reflected the acquisition of Routejade, a Korean battery maker, and a deal to produce battery cells for the U.S. Army to help power soldiers' communication and navigation equipment. Shares jumped 10.7% after hours. The company reported sales of $200,000 in the third quarter, in line with FactSet estimates, and an adjusted per-share loss of 19 cents, better than the 25-cent loss expected.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-07-23 1823ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters